organization · Reporting owner
Westlake BioPartners Fund I, L.P.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Electra Therapeutics, Inc.ETRA · Entity 9265 | 10% owner | September 21, 2026 | September 22, 2026 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | 10% owner | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Electra Therapeutics, Inc.
Report date September 21, 2026 · Filed September 22, 2026
Jointly reported with Westlake BioPartners GP I, LLC, Westlake BioPartners Fund II, L.P., Westlake BioPartners GP II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,527,136 |
Reported balance
Holding disclosure · report date 2026-09-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,527,136 F3: Shares acquired upon the automatic conversion of redeemable preferred stock on a 1:1 basis upon the closing of the Issuer's initial public offering without the payment of further consideration. Each Reporting Person had previously waived its right to voluntarily convert such redeemable preferred stock. F1: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (Seidenberg) is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,820,403 |
Reported balance
Holding disclosure · report date 2026-09-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,820,403 F3: Shares acquired upon the automatic conversion of redeemable preferred stock on a 1:1 basis upon the closing of the Issuer's initial public offering without the payment of further consideration. Each Reporting Person had previously waived its right to voluntarily convert such redeemable preferred stock. F2: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (Seidenberg) is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F2: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F3: Shares acquired upon the automatic conversion of redeemable preferred stock on a 1:1 basis upon the closing of the Issuer's initial public offering without the payment of further consideration. Each Reporting Person had previously waived its right to voluntarily convert such redeemable preferred stock.
Latigo Biotherapeutics, Inc.
Report date August 10, 2026 · Filed August 11, 2026
Jointly reported with Westlake BioPartners GP I, LLC, Westlake BioPartners Fund II, L.P., Westlake BioPartners GP II, LLC, Westlake BioPartners Opportunity Fund I, L.P., Westlake BioPartners Opportunity GP I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,368,532 |
Reported balance
After 2026-08-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-10 · Conversion · Acquired 938,979 · Balance 1,368,532 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,916,374 |
Reported balance
After 2026-08-10 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-08-10 · Conversion · Acquired 3,547,842 · Balance 4,916,374 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,944,009 |
Reported balance
After 2026-08-10 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-08-10 · Conversion · Acquired 1,027,635 · Balance 5,944,009 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,510,927 |
Reported balance
After 2026-08-10 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-08-10 · Conversion · Acquired 3,464,072 · Balance 3,510,927 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,995,328 |
Reported balance
After 2026-08-10 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-08-10 · Conversion · Acquired 1,484,401 · Balance 4,995,328 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,160,847 |
Reported balance
After 2026-08-10 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2026-08-10 · Conversion · Acquired 165,519 · Balance 5,160,847 F4: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,094,813 |
Reported balance
After 2026-08-10 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2026-08-10 · Conversion · Acquired 2,066,857 · Balance 2,094,813 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Opportunity Fund"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC ("Opportunity GP"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Series Seed Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Conversion · Disposed 938,979 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Conversion · Disposed 3,547,842 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-10 · Conversion · Disposed 1,027,635 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-10 · Conversion · Disposed 3,464,072 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-10 · Conversion · Disposed 2,066,857 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Opportunity Fund"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC ("Opportunity GP"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-10 · Conversion · Disposed 1,484,401 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-10 · Conversion · Disposed 165,519 · Balance 0 F4: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F3: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F4: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.
F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Opportunity Fund"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC ("Opportunity GP"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kyverna Therapeutics, Inc.
Report date December 18, 2025 · Filed December 22, 2025
Jointly reported with Westlake BioPartners Opportunity Fund I, L.P., Westlake BioPartners Opportunity GP I, LLC, Westlake BioPartners GP I, LLC
Section 16 reporting ended · disclosed 2025-12-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 869,317 |
Reported balance
After 2025-12-18 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-12-18 · Purchase · Acquired 133,333 · Balance 869,317 F1: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is held by the managing director of Westlake Opportunity GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake Opportunity's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,787,940 |
Reported balance
Holding disclosure · report date 2025-12-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,787,940 F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is held by the managing director of Westlake GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake I's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake GP I, and accordingly, is not a Reporting Person on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is held by the managing director of Westlake Opportunity GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake Opportunity's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Form 4.
F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is held by the managing director of Westlake GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake I's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake GP I, and accordingly, is not a Reporting Person on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionConvertible Promissory Note · Derivative | 165,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 14 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 165,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F4 · price: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F4 · derivative.exercise_date: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F4 · derivative.expiration_date: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 2,066,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 13 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,066,857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5 · ownership.nature: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Opportunity Fund"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC ("Opportunity GP"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,484,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 12 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,484,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 3,464,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 11 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,464,072 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 1,027,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 10 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,027,635 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,547,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 9 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,547,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionSeries Seed Convertible Preferred Stock · Derivative | 938,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 8 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 938,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 2,066,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 7 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,094,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5 · ownership.nature: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Opportunity Fund"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC ("Opportunity GP"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 165,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 6 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,160,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 1,484,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 5 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,995,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 3,464,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 4 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,510,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 1,027,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 3 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,944,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 3,547,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 2 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,916,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC | Latigo Biotherapeutics, Inc. LTGO · Entity 4709 | ConversionCommon Stock | 938,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 1 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,368,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 16:42 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | PurchaseCommon Stock | 133,333 | $7.50 | $999,997.50 |
DisclosureSEC source: 0001104659-25-123596 · tm2534053-1_4seq1.xml · nonDerivative · entry 1 Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 869,317 F1 · ownership.nature: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is held by the managing director of Westlake Opportunity GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake Opportunity's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Form 4. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 3,349,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-024091 · tm246188-1_4seq1.xml · derivative · entry 6 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Harper Sean E · CIK 0001541946 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 735,984 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 4,006,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-024091 · tm246188-1_4seq1.xml · derivative · entry 5 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Harper Sean E · CIK 0001541946 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 880,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries A-2 Redeemable Convertible Preferred Stock · Derivative | 8,830,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-024091 · tm246188-1_4seq1.xml · derivative · entry 4 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Harper Sean E · CIK 0001541946 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,940,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries A-1 Redeemable Convertible Preferred Stock · Derivative | 4,401,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-024091 · tm246188-1_4seq1.xml · derivative · entry 3 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Harper Sean E · CIK 0001541946 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 967,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionCommon Stock | 735,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-024091 · tm246188-1_4seq1.xml · nonDerivative · entry 2 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Harper Sean E · CIK 0001541946 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 735,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F1 · price: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F3 · ownership.nature: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionCommon Stock | 3,787,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-024091 · tm246188-1_4seq1.xml · nonDerivative · entry 1 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Harper Sean E · CIK 0001541946 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,787,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F1 · price: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.